"Jumping genes" within eggs determine their survival

Researchers find many psychiatric disorders share the same gene variants The team wrote that in most cases the fertility of human females and other mammals is dependent on the “size and quality of the ovarian reserve of primordial follicles, a supply of arrested oocytes and associated somatic cells established by birth.” They added, “Paradoxically, the ovarian reserve of primordial follicles at birth reflects only a smaller share (~20% in humans) of all oocytes initially specified in the fetal ovary. The majority of fetal oocytes generated are lost by fetal oocyte attrition (FOA), a conserved phenomenon among mammals.” Barbara McClintock from the same institute first discovered the jumping gene. She found that this gene is capable of moving within the genetic work up of the cellular DNA and may even break the genes or introduce new mutations and changes that help the species to survive or live on. This study by McClintock, was followed by Bortvin and colleagues’ research where they noted that this jumping gene could be removed during production of the sperms but were unharmed during oocyte or egg development. The earlier study by Bortvin and colleagues showed that cells that contained most activity of the gene LINE-1 were removed first and this allowed that immature oocytes which had the lowest risk of dying due to the jumping genes. Malki and Bortvin had also showed before that a particular drug AZT could help inhibit the multiplication of LINE-1. AZT incidentally is a drug used against HIV multiplication as well and is called azidothymidine, an inhibitor of reverse transcriptase. When AZT was used, the deaths of the immature egg’s cells were stopped, the team had found. They concluded that cells with excess LINE-1 activity were thus detected as eliminated by several mechanisms. In this new study the scientists collaborated and used lab mice which were genetically tweaked to lack a protein called Chk2. This protein plays a role in detecting DNA damage within cells and can work by either repairing the damage or ear marking the DNA damaged cells so that these cells could be programmed for death. These mice lacking the Chk2 proetin were now given AZT to inhibit their LINE-1 function. Results revealed that the number of surviving immature eggs cells rose. Tharp said in a statement, “What's more, the shutting off the fetal egg cell elimination process in this way did not decrease fertility. This provides further evidence that this is a quality control process undertaken to try to maintain the caliber of the available egg supply.” As a next step the team is working on ways in which these findings could help women suffering from infertility due to premature ovarian failure. They speculate that inhibition of elimination of immature eggs cells could help increase the total egg supply in a female with infertility. The authors also wrote in conclusion, “Future studies analyzing retrotransposition frequency and mutations in a larger pedigree from Chk2−/− +AZT females that did not experience FOA will answer these big questions of whether lack of quality control in fetal oogenesis manifests in the disease susceptibility or adaptive potential of future generations.” This study was funded by National Institutes of Health. Journal reference: Tharp, M.E., Malki, S. & Bortvin, A. Maximizing the ovarian reserve in mice by evading LINE-1 genotoxicity. Nat Commun 11, 330 (2020) doi:10.1038/s41467-019-14055-8, https://www.nature.com/articles/s41467-019-14055-8



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More